Research any topic before you write.
Find related topics. | Discover entities. | See connections. | Build a topical map.
Sofosbuvir, sold under the brand name Sovaldi among others, is a medication used to treat hepatitis C. It is taken by mouth.
The analysis highlights History, Community, Culture and Applications as prominent areas in the source structure around Sofosbuvir. 1 topic appears in more than one source area, which can help identify connections that are less obvious in a linear reading.
Source areas are shown by the number of related topics found in each part of the analysis. Use smaller areas too: they can reveal specialized angles and content gaps.
Smaller areas are not necessarily less important. They contain fewer connections in this analysis and can be useful for finding specialized angles or coverage gaps.
High-confidence facts extracted from structured source data. Use them as anchors for further research.
Browse the complete topic structure, not only the most central items. Less prominent entities and concepts can reveal missing angles, specialized context and useful research gaps. Each item opens a new analysis centered on that subject.
Deeper signals for content research, entity SEO and topical coverage. The plain-language headings explain what each technical view is useful for.
The extracted context around Sofosbuvir shows recurring relationship patterns in the source. For example, Sofosbuvir → April, FDA, FDA's Breakthrough Therapy Designation, Gilead, Gilead Sciences, HCV, In, In December, Michael, New Drug Application, NS5A, October, Pharmasset, RBV, Sofia, Two Another extracted example is Sofosbuvir → Biotechnology Information, Bookshelf ID, Dean, IFNL4 Genotype, In Pratt VM, McLeod HL, Medical Genetics Summaries, National Center, NBK409960, NCBI, PMID, Rubinstein WS, Sofosbuvir Therapy. Use these groups to spot repeated connection types before inspecting the individual relationships.
Use these terms to understand the vocabulary surrounding the topic, not as a checklist for keyword stuffing.
treatment hepatitis price gilead combination drug ribavirin used people 000 india also side effects ledipasvir 2015 protein would 2014 government
TTTA extracted 166 structured relationships around Sofosbuvir. Examples in this analysis include Sofosbuvir → 3D model (JSmol) → Interactive image and Sofosbuvir → AHFS/Drugs.com → Monograph. The table shows each extracted connection, where it came from and its confidence.
| Subject | Predicate | Object | Confidence | Src |
|---|---|---|---|---|
| Sofosbuvir | 3D model (JSmol) | Interactive image | 1.00 | infobox |
| Sofosbuvir | AHFS/Drugs.com | Monograph | 1.00 | infobox |
| Sofosbuvir | ATC code | J05AP08 (WHO) J05AP51 (WHO) J05AP55 (WHO) J05AP56 (WHO) | 1.00 | infobox |
| Sofosbuvir | Bioavailability | 92% | 1.00 | infobox |
| Sofosbuvir | CAS Number | 1190307-88-0 | 1.00 | infobox |
| Sofosbuvir | ChEBI | CHEBI:85083 Y | 1.00 | infobox |
| Sofosbuvir | ChEMBL | ChEMBL1259059 | 1.00 | infobox |
| Sofosbuvir | ChemSpider | 26286922 | 1.00 | infobox |
| Sofosbuvir | CompTox Dashboard (EPA) | DTXSID701027632 | 1.00 | infobox |
| Sofosbuvir | Drug class | HCV polymerase inhibitor | 1.00 | infobox |
| Sofosbuvir | DrugBank | DB08934 | 1.00 | infobox |
| Sofosbuvir | ECHA InfoCard | 100.224.393 | 1.00 | infobox |
| Sofosbuvir | Elimination half-life | 0.4 hrs (sofosbuvir) 27 hrs (inactive metabolite GS-331007) | 1.00 | infobox |
| Sofosbuvir | Excretion | 80% urine, 14% feces (mostly as GS-331007) | 1.00 | infobox |
| Sofosbuvir | Formula | C22H29FN3O9P | 1.00 | infobox |
| Sofosbuvir | IUPHAR/BPS | 7368 | 1.00 | infobox |
| Sofosbuvir | KEGG | D10366 | 1.00 | infobox |
| Sofosbuvir | Legal status | AU: S4 (Prescription only) | 1.00 | infobox |
| Sofosbuvir | Legal status | UK: POM (Prescription only) | 1.00 | infobox |
| Sofosbuvir | Legal status | US: ℞-only | 1.00 | infobox |
| Sofosbuvir | Legal status | EU: Rx-only | 1.00 | infobox |
| Sofosbuvir | License data | EU EMA: by INN | 1.00 | infobox |
| Sofosbuvir | License data | US DailyMed: Sofosbuvir | 1.00 | infobox |
| Sofosbuvir | License data | US FDA: Sofosbuvir | 1.00 | infobox |
| Sofosbuvir | MedlinePlus | a614014 | 1.00 | infobox |
| Sofosbuvir | Metabolism | Quickly activated to triphosphate (CatA/CES1, HIST1, phosphorylation) | 1.00 | infobox |
| Sofosbuvir | Molar mass | 529.458 g·mol−1 | 1.00 | infobox |
| Sofosbuvir | Other names | PSI-7977; GS-7977 | 1.00 | infobox |
| Sofosbuvir | Pregnancy category | AU: B1 | 1.00 | infobox |
| Sofosbuvir | Protein binding | 61–65% | 1.00 | infobox |
The concept neighborhoods around Sofosbuvir bring nearby vocabulary together. In this analysis, examples include Hepatitis, Combination and Treatment. Use the clusters to find adjacent concepts and terminology that may deserve separate research.
For Sofosbuvir, one of the stronger structural bridges in this analysis connects Sofosbuvir with Overview. Bridges highlight paths between different parts of the map and can reveal research angles that are easy to miss in a flat list.
TTTA analyzes the structure around Sofosbuvir to surface related topics, entities, relationships, concept neighborhoods and bridge connections. Use the map to explore areas such as History, Community, Culture & Applications, including less central topics that may reveal useful research gaps. Automatically extracted connections are research leads rather than rewritten encyclopedia content.
Source: Wikipedia — Sofosbuvir · EN edition · Analysis: TopicsToTalkAbout